B. Metzler seel. Sohn & Co. AG Acquires Shares of 231,381 Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 231,381 Vertex shares worth approximately $114.9 million, making Vertex a 1.0% holding and its 22nd-largest position. Institutional investors collectively own 90.96% of the company.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $563.50; several firms recently raised their targets to between $570 and $617.
• Vertex reported quarterly revenue of $3.33 billion, up 12.5% year over year and above estimates, though EPS narrowly missed expectations. Its pipeline offers growth potential through inaxaplin and the proposed Crinetics acquisition, which faces shareholder-related execution risks.

B. Metzler seel. Sohn & Co. AG bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 231,381 shares of the pharmaceutical company's stock, valued at approximately $114,934,000. Vertex Pharmaceuticals comprises approximately 1.0% of B. Metzler seel. Sohn & Co. AG's holdings, making the stock its 22nd biggest holding. B. Metzler seel. Sohn & Co. AG owned approximately 0.09% of Vertex Pharmaceuticals at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $26,000. Community Financial Services Group LLC acquired a new position in Vertex Pharmaceuticals during the second quarter worth approximately $26,000. Elevation Wealth Partners LLC lifted its stake in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 28 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $26,000. Finally, Swiss RE Ltd. purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $28,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an "overweight" rating in a report on Tuesday, May 5th. Sanford C. Bernstein raised Vertex Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, July 29th. Royal Bank Of Canada boosted their price target on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an "outperform" rating in a research report on Tuesday, July 7th. Stifel Nicolaus set a $500.00 price objective on Vertex Pharmaceuticals in a research note on Tuesday, August 4th. Finally, Barclays increased their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $563.50.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex completed the Phase 2b trial of inaxaplin, its treatment candidate for APOL1-mediated kidney disease. The milestone advances a potentially important non-cystic-fibrosis growth driver and could support future regulatory and commercialization plans. Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
• Positive Sentiment: Wall Street remains optimistic about VRTX, with BMO Capital reiterating a Buy rating. Analysts point to Vertex’s leadership in cystic fibrosis and potential contributions from newer products and pipeline programs. Vertex Pharmaceuticals Receives a Buy from BMO Capital
• Positive Sentiment: Recent commentary describes cystic fibrosis as a continuing “engine” for Vertex’s rally, suggesting investors expect durable cash generation and additional growth from the company’s dominant franchise. Vertex Pharmaceuticals’ Rally Has a New Engine — and Wall Street Thinks the Best Is Still Ahead
• Neutral Sentiment: Vertex is reportedly entering a new healthcare focus, indicating a broader strategic emphasis beyond its established cystic fibrosis business. The longer-term impact will depend on the specific programs, investment requirements, and commercial potential. Vertex Pharmaceuticals Enters New Healthcare Focus
• Negative Sentiment: Shareholder challenges to Vertex’s proposed acquisition of Crinetics Pharmaceuticals create execution and deal-completion risk. Delays, litigation, or a higher acquisition cost could weigh on sentiment, even though the transaction is intended to expand Vertex’s pipeline. Crinetics Faces Shareholder Challenges to Vertex Merger Deal

Vertex Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ VRTX opened at $540.26 on Friday. The stock has a market cap of $137.12 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 2.28 and a beta of 0.30. The company's 50-day moving average price is $490.59 and its 200 day moving average price is $465.35. Vertex Pharmaceuticals Incorporated has a 52 week low of $374.17 and a 52 week high of $553.69.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.The firm had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period in the prior year, the business earned $4.52 earnings per share. Vertex Pharmaceuticals's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.86 earnings per share for the current year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 1,541 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the transaction, the executive vice president directly owned 11,001 shares of the company's stock, valued at $5,709,519. This represents a 12.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the company's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the completion of the sale, the executive vice president directly owned 45,321 shares in the company, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 10,464 shares of company stock valued at $4,959,397. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source